Therapeutic Potential of the Molecular Chaperone and Matrix Metalloproteinase Inhibitor Clusterin for Dry Eye
Open Access
- 24 December 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (1) , 116
Abstract
Evidence is presented herein supporting the potential of the natural homeostatic glycoprotein CLU (clusterin) as a novel therapeutic for the treatment of dry eye. This idea began with the demonstration that matrix metalloproteinase MMP9 is required for damage to the ocular surface in mouse dry eye. Damage was characterized by degradation of OCLN (occludin), a known substrate of MMP9 and a key component of the paracellular barrier. Following up on this finding, a yeast two-hybrid screen was conducted using MMP9 as the bait to identify other proteins involved. CLU emerged as a strong interacting protein that inhibits the enzymatic activity of MMP9. Previously characterized as a molecular chaperone, CLU is expressed prominently by epithelia at fluid-tissue interfaces and secreted into bodily fluids, where it protects cells and tissues against damaging stress. It was demonstrated that CLU also protects the ocular surface in mouse dry eye when applied topically to replace the natural protein depleted from the dysfunctional tears. CLU is similarly depleted from tears in human dry eye. The most novel and interesting finding was that CLU binds selectively to the damaged ocular surface. In this position, CLU protects against epithelial cell death and barrier proteolysis, and dampens the autoimmune response, while the apical epithelial cell layer is renewed. When present at high enough concentration, CLU also blocks staining by vital dyes used clinically to diagnose dry eye. None of the current therapeutics have this combination of properties to “protect, seal, and heal”. Future work will be directed towards human clinical trials to investigate the therapeutic promise of CLU.Keywords
Funding Information
- National Eye Institute (EY026479)
- Massachusetts Lions Eye Research Fund (none)
- Research to Prevent Blindness (none)
This publication has 117 references indexed in Scilit:
- Protease‐activated alpha‐2‐macroglobulin can inhibit amyloid formation via two distinct mechanismsFEBS Letters, 2013
- Allogeneic Serum Eye Drops for the Treatment of Dry Eye Patients with Chronic Graft-Versus-Host DiseaseJournal of Ocular Pharmacology and Therapeutics, 2012
- Interaction of Clusterin and Matrix Metalloproteinase-9 and Its Implication for Epithelial Homeostasis and InflammationThe American Journal of Pathology, 2012
- Fluorescein Punctate Staining Traced to Superficial Corneal Epithelial Cells by Impression Cytology and Confocal MicroscopyInvestigative Ophthalmology & Visual Science, 2011
- Structural Characterization of Clusterin-Chaperone Client Protein ComplexesJournal of Biological Chemistry, 2009
- Association of Cell Surface Mucins with Galectin-3 Contributes to the Ocular Surface Epithelial BarrierJournal of Biological Chemistry, 2009
- Production and Activity of Matrix Metalloproteinase-9 on the Ocular Surface Increase in Dysfunctional Tear SyndromeInvestigative Ophthalmology & Visual Science, 2009
- The Ocular Surface: The Challenge to Enable and Protect VisionInvestigative Ophthalmology & Visual Science, 2007
- Control of matrix metalloproteinase catalytic activityMatrix Biology, 2007
- Matrix metalloproteinases and the regulation of tissue remodellingNature Reviews Molecular Cell Biology, 2007